Abstract:Bruton tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a major therapeutic target for B-cell-driven malignancies. However, approved covalent BTK inhibitors (cBTKis) are associated with treatment limitations because of off-target side effects, suboptimal oral pharmacology, and development of resistance mutations (eg, C481) that prevent inhibitor binding. Here, we describe the preclinical profile of pirtobrutinib, a potent, highly selective, noncovalent (reversible) BTK inhibitor. Pirtobrutinib binds BTK with an extensive network of interactions to BTK and water molecules in the adenosine triphosphate binding region and shows no direct interaction with C481. Consequently, pirtobrutinib inhibits both BTK and BTK C481 substitution mutants in enzymatic and cell-based assays with similar potencies. In differential scanning fluorimetry studies, BTK bound to pirtobrutinib exhibited a higher melting temperature than cBTKi-bound BTK. Pirtobrutinib, but not cBTKis, prevented Y551 phosphorylation in the activation loop. These data suggest that pirtobrutinib uniquely stabilizes BTK in a closed, inactive conformation. Pirtobrutinib inhibits BTK signaling and cell proliferation in multiple B-cell lymphoma cell lines, and significantly inhibits tumor growth in human lymphoma xenografts in vivo. Enzymatic profiling showed that pirtobrutinib was highly selective for BTK in >98% of the human kinome, and in follow-up cellular studies pirtobrutinib retained >100-fold selectivity over other tested kinases. Collectively, these findings suggest that pirtobrutinib represents a novel BTK inhibitor with improved selectivity and unique pharmacologic, biophysical, and structural attributes with the potential to treat B-cell-driven cancers with improved precision and tolerability. Pirtobrutinib is being tested in phase 3 clinical studies for a variety of B-cell malignancies.

Discovery of new non-covalent reversible BTK inhibitors: Synthesis, in silico studies, and in vitro evaluations

Discovery of Novel BTK PROTACs for B-Cell Lymphomas.

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Recent Research of BTK Inhibitors: Methods of Structural Design, Pharmacological Activities, Manmade Derivatives and Structure-Activity Relationship.

Discovery of Pyrido[3,4-B]indol-1-one Derivatives As Novel Non-Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a Pyrrolo[2,3-D]pyrimidine Scaffold

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor

Discovery of Pyrrolo[1,2-A]quinoxalin-4(5h)-one Derivatives As Novel Non-Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of 1-Amino-1 H -imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas

Novel 6-Amino-1,3,5-triazine Derivatives As Potent BTK Inhibitors: Structure-Activity Relationship (SAR) Analysis and Preliminary Mechanism Investigation.

Discovery and Biological Evaluation of N5-substituted 6,7-Dioxo-6,7-dihydropteridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Discovery of Pteridine-7(8H)-one Derivatives As Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases

Design, Synthesis and Biological Evaluation of Novel 2-Phenyl Pyrimidine Derivatives As Potent Bruton's Tyrosine Kinase (BTK) Inhibitors.